US 11,833,147 B2
Procaspase 3 activation by combination therapy
Paul J. Hergenrother, Champaign, IL (US); Rachel C. Botham, Champaign, IL (US); Timothy M. Fan, Mahomet, IL (US); Mark J. Gilbert, Seattle, WA (US); Michael K. Handley, Windsor, CO (US); Howard S. Roth, Champaign, IL (US); and Theodore M. Tarasow, San Ramon, CA (US)
Assigned to Vanquish Oncology, Inc., Champaign, IL (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed by The Board of Trustees of the University of Illinois, Urbana, IL (US); and Vanquish Oncology, Inc., Champaign, IL (US)
Filed on Jan. 8, 2021, as Appl. No. 17/144,926.
Application 17/144,926 is a continuation of application No. 16/148,303, filed on Oct. 1, 2018, granted, now 10,888,560.
Application 16/148,303 is a continuation of application No. 15/220,361, filed on Jul. 26, 2016, granted, now 10,085,977, issued on Oct. 2, 2018.
Application 15/220,361 is a continuation of application No. 14/383,441, granted, now 9,399,035, issued on Jul. 26, 2016, previously published as PCT/US2013/029405, filed on Mar. 6, 2013.
Claims priority of provisional application 61/607,098, filed on Mar. 6, 2012.
Prior Publication US 2021/0128551 A1, May 6, 2021
Int. Cl. A61K 31/495 (2006.01); A61K 33/243 (2019.01); A61K 9/08 (2006.01); A61K 31/138 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/496 (2006.01); A61K 31/553 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 33/24 (2019.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/495 (2013.01) [A61K 9/008 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/4858 (2013.01); A61K 31/138 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/496 (2013.01); A61K 31/553 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 33/24 (2013.01); A61K 33/243 (2019.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01)] 6 Claims
 
1. A method of treating cancer comprising administering to a subject in need thereof an effective amount of PAC-1:

OG Complex Work Unit Chemistry
and an effective amount of sunitinib, wherein sunitinib is synergistic with PAC-1 in the treatment of the cancer, wherein PAC-1 has a concentration of about 2.5 μM to about 10 μM, sunitinib has a concentration of about 100 nM to about 10 μM, and the cancer is a carcinoid tumor.